Jan van Oostrum has left Novartis to become head of business development at Zeptosens, he told ProteoMonitor this week. He will start at Zeptosens next month.
In his new position, van Oostrum will further develop the company’s reverse array platform and identify new application areas. At Novartis, he was head of protein sciences and technologies and implemented reverse protein microarrays for a number of applications. Van Oostrum is also co-chair of the Human Proteome Organization’s Industry Advisory Board.
Proteomics start-up Caprotec Bioanalytics this week told ProteoMonitor the members of its scientific board. They are, Hubert Köster, the founder and CEO of the company; Ira Goldfine, a professor at the University of California, San Francisco; Franz Hillenkamp, Director Emeritus at the Institute of Medical physics and Biophysics at the University of Münster, Germany, and co-inventor of MALDI-MS; Joseph Loo, professor at the University of California, Los Angeles; John Walker, winner of the 1997 Nobel Prize in chemistry; and Ernst Mutschler, professor and Director Emeritus at the Institute of Pharmacology at the University of Frankfurt/Main in Germany.
GenoLogics this week announced Sal Sanci and Paul Ford have joined the company.
Sanci is vice president of products. Prior to joining GenoLogics, he was VP of technology at Teligence. In his new post, he will oversee the software development, QA, and product management teams.
Ford is VP of finance. He comes to GenoLogics from private equity firm PineRidge Partners in Tokyo where he was executive director.
GenoLogics also said that James DeGreef, the company’s founder, is now VP of market strategy. He had served as VP of product management. And Don Listwin was appointed chairman of the company’s board of directors. Listwin is the founder of the Canary Foundation.
Proxeon last week said that John Chakel has been appointed vice president of North America Business Development. He had been VP of North America Business Operations.